CD8A and neoplasm: Whereas OV has been well recognized as a strong activator of anti-tumor immunity and produces an abscopal effect on metastatic lesions, mainly brought about by temporal effector CD8 + T cells of SLECs, little is known about the effect of OV on long-term anti-tumor immunity, as with conventional chemotherapy and radiotherapy.